Juno therapeutics stock price history

Nov 01, 2017 · Unless the context requires otherwise, in this Quarterly Report on Form 10-Q, the terms "Juno," "Company," "we," "us" and "our" refer to Juno Therapeutics, Inc., a Delaware corporation, and its Juno Therapeutics Stock News, Analysis & Forecast for ... JUNO Stock: The Next Move Is Almost Upon Us The stock market is red hot and new all-time highs are a daily occurrence. The market is sizzling, which allows for sizable moves to develop. Juno Therapeutics (JUNO) Stock: An Option Trader's Dream ... Jul 13, 2016 · Juno Therapeutics (JUNO) Stock: An Option Trader's Dream. Wild volatility, high volume make Juno Therapeutics a hot name in the options market. Juno Therapeutics acquired by Celgene for $9B in dramatic ...

Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, 

Celgene Corporation, incorporated in Delaware and headquartered in Summit, New Jersey, Celgene shareholders would receive one BMY share as well as $50 in cash for each The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):. 7 Dec 2018 Moderna Therapeutics Sets Record for Biggest Biotech IPO The company sold approximately 26.3 million shares priced at $23 a share. And a year before them, in 2014, Juno Therapeutics raised $264 The company has been secretive over its history, which it could be because it was privately owned  22 Jan 2018 Celgene already owns 9.7 percent in Juno and will offer $87 per share. Premarket prices of Juno Therapeutics jump on the news. JUNO / Juno Therapeutics, Inc. - Institutional Ownership and Shareholders The chart to the right plots the historical put/call ratio for this instrument. Using Put/Call File Date, Form, Investor, Opt, Avg Share Price, Shares, Shares Changed Records 1 - 18 of 21 Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2019, EDGAR®Online, a division of 

Juno Therapeutics Inc - Company Profile and News ...

Jan 22, 2018 · Juno Therapeutics, the Seattle-based biotech company making cutting-edge cancer immunotherapy treatments, has reached a deal to be acquired by New Jersey-based Celgene for $9 billion, or $87 per Juno’s Top Holder Sells $216 Million in Stock - Barron's